BioSpace News Archive

Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials, announced financial results for the quarter ended March 31, 2023.

Soleno Therapeutics, Inc. announced that it has completed enrollment in the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced that it has commenced an underwritten public offering of its shares of common stock.

Zynex, Inc., announced its intent to offer, subject to market conditions and other factors, $50 million aggregate principal amount of its convertible senior notes due 2026 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2023.

Nanalysis Scientific Corp. is pleased to announce, further to its news releases dated April 21, 2023, April 26, 2023 and May 1, 2023, it has successfully closed the second and final tranche of its $4,128,700 non-brokered private placement.

10x Genomics, Inc. reported financial results for the first quarter ended March 31, 2023.

Eiger BioPharmaceuticals, Inc. reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger’s common stock.

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada.

REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the first quarter ended March 31, 2023, and recent operational highlights.